Updates are available Correction dated 2025-04-07
Click to view Correction: https://doi.org/10.1186/s40644-025-00870-4
-
Authors
Zschaeck, Sebastian https://orcid.org/0000-0003-3109-0662
Hajiyianni, Marina
Hausmann, Patrick
Nikulin, Pavel
Kukuk, Emily
Furth, Christian
Cegla, Paulina
Lombardo, Elia
Kazmierska, Joanna
Holzgreve, Adrien
Strouthos, Iosif
Stromberger, Carmen
Belka, Claus
Baumann, Michael
Krause, Mechthild
Landry, Guillaume
Cholewinski, Witold
Kotzerke, Jorg
Zips, Daniel
van den Hoff, Jörg
Hofheinz, Frank
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 29 December 2024
Accepted: 6 February 2025
First Online: 21 February 2025
Change Date: 7 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40644-025-00870-4
Declarations
:
: This study was approved by the Institutional Ethics Committee of Charité University Clinic Berlin. Ethics application No. EA1/241/22. Patients treated within prospective studies gave written informed consent to participate. For patients with retrospective evaluation of data, informed consent was waived by the committee due to the retrospective nature of the study.
: The authors affirm that human research participants provided informed consent for publication of pseudonymized publication of the data.
: Adrien Holzgreve is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)– 545058105, and reports compensation for scientific consulting by ABX advanced biochemical compounds outside the submitted work. Dr. Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards, and boards of trustees. Dr. Baumann confirms that there is no conflict of interest for this paper. Dr. Baumann confirms that, to the best of his knowledge, none of the above funding sources were involved in the preparation of this paper. Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018), Attomol GmbH (2019–2021), GA Generic Assays GmbH (2019–2021), BTU Cottbus-Senftenberg (2019–2021), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2021), Lipotype GmbH (2019–2021), PolyAn GmbH (2019–2021). All other authors have nothing to disclose.
